Pancreatic cancer mRNA vaccine shows lasting results in an early trial
Kişiselleştirilmiş mRNA pankreas kanseri aşısına yanıt veren hastaların neredeyse hepsi altı yıl sonra hayatta kalmaya devam etmektedir. Erken dönem deneyler umut verici sonuçlar göstermektedir.
A personalized mRNA vaccine designed to target pancreatic cancer has demonstrated sustained effectiveness in a preliminary study. Six years after receiving the vaccine, the vast majority of patients who showed a positive response are still alive. This early trial suggests a promising long-term benefit for individuals treated with this innovative approach.
This development offers a potential new avenue for treating pancreatic cancer, a disease with historically poor survival rates.
📌 Kaynak
Bu özet nbcnews kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →